Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of “Buy” by Brokerages

Zura Bio Limited (NASDAQ:ZURA) has been given an average recommendation of “Buy” by the seven ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $11.60.

A number of research firms have recently weighed in on ZURA. HC Wainwright lowered their target price on Zura Bio from $3.00 to $2.00 and set a “neutral” rating for the company in a research note on Tuesday, August 19th. Oppenheimer reduced their price target on Zura Bio from $17.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, August 15th. Finally, Chardan Capital restated a “buy” rating and set a $10.00 price target on shares of Zura Bio in a report on Friday, August 15th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Millennium Management LLC increased its holdings in Zura Bio by 1,499.0% during the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock valued at $1,753,000 after purchasing an additional 657,420 shares during the period. Allostery Investments LP increased its holdings in Zura Bio by 44.2% during the 1st quarter. Allostery Investments LP now owns 2,329,384 shares of the company’s stock valued at $3,005,000 after purchasing an additional 714,258 shares during the period. ProShare Advisors LLC purchased a new position in Zura Bio during the 4th quarter valued at about $35,000. Two Sigma Advisers LP purchased a new position in shares of Zura Bio during the 4th quarter worth approximately $32,000. Finally, Northern Trust Corp grew its holdings in shares of Zura Bio by 16.7% during the 4th quarter. Northern Trust Corp now owns 401,994 shares of the company’s stock worth $1,005,000 after acquiring an additional 57,583 shares during the period. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Trading Down 8.3%

NASDAQ ZURA opened at $2.10 on Friday. Zura Bio has a 1-year low of $0.97 and a 1-year high of $5.07. The stock has a 50-day moving average of $1.84 and a 200-day moving average of $1.44. The firm has a market cap of $136.54 million, a PE ratio of -3.00 and a beta of -0.02.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. As a group, equities research analysts forecast that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.